High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

Haematologica

Volumn 93, Issue 2, 2008, Pages 207-214

  Montoto, Silvia ^a   Moreno, Carol ^a   Domingo Doménech, Eva ^b   Estany, Cristina ^c   Oriol, Albert ^d   Altés, Albert ^e   Besalduch, Joan ^f   Pedro, Carme ^g   Gardella, Santiago ^h   Escoda, Lourdes ⁱ   Asensio, Antoni ^j   Vivancos, Pilar ^k   Galán, Pilar ^c   De Sevilla, Alberto Fernández ^b   Ribera, Josep M ^d   Briones, Javier ^e   Colomer, Dolors ^a   Campo, Elías ^a   Montserrat, Emili ^a   López Guillermo, Armando ^a,l  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c Mútua de Terrassa ^*

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h Dr Trueta University Hospital   (Spain)

ⁱ HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^j Hospital Sant Camil   (Spain)

^k CENTRO MÉDICO TEKNON   (Spain)

^l HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Follicular lymphoma; Molecular response; Outcome; Treatment

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; MITOXANTRONE; RITUXIMAB;

ADULT; ADVANCED CANCER; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RESPIRATORY TRACT INFECTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; RECURRENCE; SURVIVAL RATE; VIDARABINE;

EID: 40949154392     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11671     Document Type: Article

References (40)

1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
2. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
3. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582-9.
4. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7.
5. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998;91:2955-60.
6. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-33.
7. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527-36.
8. + cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin's lymphoma. Blood 2005;105:3428-33.
9. McLaughlin P, Hagemeister FB, Swan F Jr, Cabanillas F, Pate O, Romaguera JE, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994;12:575-9.
10. th Annual Meeting of the American Society of Hematology 1997:2360.
11. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002;119:976-84.
12. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in Bcell chronic lymphocytic leukemia. Blood 1999;94:2836-43.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
15. Gribben JG, Freedman A, Woo SD, Blake K, Shu RS, Freeman G, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991;78:3275-80.
16. Estalilla OC, Medeiros LJ, Manning JT Jr, Luthra R. 5′→ 3′ exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol 2000;13:661-6.
17. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
18. Moreno C, López-Guillermo A, Montoto S, Domingo-Doménech E, Ribera J, Altés A, et al. Molecular assessment by BCL-2/JH quantitative PCR technique of patients (pts) with follicular lymphoma (FL) in advanced stage treated with FCM (fludarabine, cyclophosphamide and mitoxantrone). Paper presented at the IX International Conference on Malignant Lymphoma, Lugano, Switzerland 2005;248.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1-10.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 1973;29:579-84.
22. Cox DR. Regression models and life tables. J R Stat Assoc 1972;34:187-220.
23. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002;100:4351-7.
24. Hochster HS, Oken MM, Winter JN, Gordon LI, Raphael BG, Bennett JM, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987-94.
25. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as firstline treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
26. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
27. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71.
28. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654-61.
29. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005;104:345-53.
30. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-8.
31. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103:235-42.
32. Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M, the German CLL Study Group (GCLLSG). Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 2007;136:63-72.
33. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000;1:367-73.
34. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363-5.
35. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454-60.
36. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878-84.
37. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006;91:1546-50.
38. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon a. Blood 2005; 105:4573-5.
39. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18:947-55.
40. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576-82.